Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
As professional antigen presenting cells (APCs) capable of eliciting primary immune responses among naïve T cells, dendritic cells (DCs) offer an attractive target for immune intervention. While some strategies for vaccination have sought to deliver antigens direct to DCs in vivo, others have pulsed...
Váldodahkkit: | Bravo, M, Davies, TJ, Fairchild, PJ |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
Bioinsights Publishing Ltd
2021
|
Geahča maid
-
Integrating next-generation dendritic Cell vaccines into the current cancer immunotherapy landscape.
Dahkki: Garg, A, et al.
Almmustuhtton: (2017) -
iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
Dahkki: Horton, C, et al.
Almmustuhtton: (2019) -
Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy.
Dahkki: Sachamitr, P, et al.
Almmustuhtton: (2012) -
Next‐generation Gene Silencers for Cancer Immunotherapy
Dahkki: Ng, Aik Seng
Almmustuhtton: (2017) -
Financial viability and technical evaluation of dendritic cell-carrying "vaccination nodes" for immunotherapy
Dahkki: Song, Andrew, M. Eng. Massachusetts Institute of Technology
Almmustuhtton: (2009)